ERBB2 and breast carcinoma: This randomized, open-label multicenter study will evaluate the efficacy and safety of adjuvant giredestrant compared with endocrine therapy of physician’s choice in participants with medium- and high-risk Stage I-III ER+ and HER2− breast cancer (ClinicalTrials.gov identifier: NCT04961996).